KEY TAKEAWAYS
- The study aimed to investigate the efficacy of permeation-enhancing compounding bases in facilitating the penetration of APIs across the skin barrier.
- Researchers concluded that the phospholipid base HMW effectively enhances percutaneous absorption of HMW drugs.
Permeation-enhancing compounding bases are crucial in enhancing the penetration of active pharmaceutical ingredients (APIs) through the skin barrier. Daniel Banov and his team aimed to focus on investigating the efficacy of these bases in facilitating the transdermal delivery of APIs.
Researchers performed an inclusive analysis to determine the percutaneous absorption of 14 C-insulin using human torso skin and the Franz skin finite dose model. Two topical test formulations were crafted for in vitro evaluation, namely insulin 1% in phospholipid base (standard) and insulin 1% in phospholipid base high molecular weights (HMW). The study assessed the mean flux of percutaneous absorption (mean flux) and the distribution of 14 C-insulin through the skin for both formulations. A two-way ANOVA was employed to identify statistical differences in the outcomes.
With the distribution of 14 C-insulin, researchers observed its presence in the stratum corneum, epidermis, and dermis. The mean flux values indicated a swift penetration upon application, reaching maximum flux at 30 minutes, followed by a gradual decline. Notably, the topical test formulation containing the phospholipid base HMW exhibited a slower decline than the standard phospholipid base formulation.
The study concluded that the phospholipid base HMW effectively enhances percutaneous absorption of HMW drugs, suggesting its potential as a valuable option for compounding pharmacists and practitioners in the percutaneous delivery of large drugs.
Source: https://pubmed.ncbi.nlm.nih.gov/38352988/
Banov D, Song G, Carvalho M, et al. (2024). Evaluation of a compounding phospholipid base for the percutaneous absorption of high molecular weight drugs using the Franz finite dose model. Skin Res Technol. 2024 Feb;30(2):e13610. doi: 10.1111/srt.13610. PMID: 38352988; PMCID: PMC10865068.
